Oncology Clinical Trials in Philadelphia, PA

As of July 2026, 403 paid clinical trials are recruiting for Oncology in Philadelphia, Pennsylvania. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

403 clinical trials for Oncology

·Clear filters·↓ Download CSV

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

for NSCLC

Drug: EP0031

21 locations incl. Los Angeles

Sponsor: Ellipses Pharma

Sex: All·Age: 18+

Code: NCT05443126·Phase 1, Phase 2·Recruiting

Apply to this trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for Pancreatic Ductal Adenocarcinoma

13 locations incl. Los Angeles

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07020221·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

for Advanced Solid Tumor

Drug: Tulmimetostat

22 locations incl. Tampa

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT04104776·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

23 locations incl. Phoenix

Sponsor: Syncromune, Inc.

Sex: Male·Age: 18+

Code: NCT06533644·Phase 2·Recruiting

Apply to this trial

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

for Cancer

11 locations incl. Los Angeles

Sponsor: Conjupro Biotherapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05948865·Phase 1·Recruiting

Apply to this trial

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

for Advanced Cancer

15 locations incl. Los Angeles

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT05557045·Phase 1·Recruiting

Apply to this trial

Study of INCB123667 in Subjects With Advanced Solid Tumors

for Solid Tumors

Drug: INCB123667

19 locations incl. Duarte

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05238922·Phase 1·Recruiting

Apply to this trial

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

for Acute Myeloid Leukemia

Drug: Revumenib

22 locations incl. Duarte

Sponsor: Syndax Pharmaceuticals

Sex: All·Age: 30 Days+

Code: NCT04065399·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

18 locations incl. La Jolla

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 18+

Code: NCT06667908·Phase 2·Recruiting

Apply to this trial

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

for Neoplasms

11 locations incl. Duarte

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06150157·Phase 1·Recruiting

Apply to this trial

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

for Non-small Cell Lung Cancer

12 locations incl. La Jolla

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06644768·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

28 locations incl. Little Rock

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07258511·Phase 3·Recruiting

Apply to this trial

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

for Recurrent Melanoma (Skin)

Drug: Nivolumab

13 locations incl. Orange

Sponsor: Perspective Therapeutics

Sex: All·Age: 18 - 90

Code: NCT05655312·Phase 1, Phase 2·Recruiting

Apply to this trial

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

for Ewing Sarcoma

23 locations incl. Scottsdale

Sponsor: Inhibrx Biosciences, Inc

Sex: All·Age: 12 - 85

Code: NCT03715933·Phase 1·Recruiting

Apply to this trial

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

for Malignant Neoplasm

17 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 1 Month - 17

Code: NCT06941272·Phase 1, Phase 2·Recruiting

Apply to this trial

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

for Advanced Solid Tumors

11 locations incl. San Diego

Sponsor: Pyxis Oncology, Inc

Sex: All·Age: 18+

Code: NCT06795412·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

for Advanced Solid Tumor

21 locations incl. Scottsdale

Sponsor: Clasp Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06778863·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

for Solid Tumor

12 locations incl. La Jolla

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT06619587·Phase 1·Recruiting

Apply to this trial

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

for B-cell Acute Lymphoblastic Leukemia

17 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 6 Months - 25

Code: NCT06395103·Phase 1, Phase 2·Recruiting

Apply to this trial

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

for Ovarian Cancer

14 locations incl. Newport Beach

Sponsor: NextCure, Inc.

Sex: All·Age: 18+

Code: NCT06774963·Phase 1·Recruiting

Apply to this trial

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

for Cancer

17 locations incl. San Francisco

Sponsor: MBrace Therapeutics

Sex: All·Age: 18+

Code: NCT06014658·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

for Advanced or Metastatic Solid Tumors

14 locations incl. Phoenix

Sponsor: 858 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06395519·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

13 locations incl. San Francisco

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting

Apply to this trial

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

for Metastatic Cancer

Drug: Apalutamide

12 locations incl. Los Angeles

Sponsor: Sun Pharmaceutical Industries Limited

Sex: Male·Age: 18+

Code: NCT05422911·Phase 2·Recruiting

Apply to this trial

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

for Carcinoma, Non-Small-Cell Lung

18 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT04165070·Phase 1, Phase 2·Recruiting

Apply to this trial

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

for Carcinoma, Non-Small-Cell Lung

18 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT04165798·Recruiting

Apply to this trial

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

for Locally Advanced Solid Tumor

21 locations incl. Orange

Sponsor: Nuvalent Inc.

Sex: All·Age: 12+

Code: NCT05384626·Phase 1, Phase 2·Recruiting

Apply to this trial

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

for Refractory Cancer

Drug: Nivolumab

13 locations incl. Stanford

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT03686124·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

for Solid Tumors

11 locations incl. Los Angeles

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05836324·Phase 1·Recruiting

Apply to this trial

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

for PROC

12 locations incl. Little Rock

Sponsor: Whitehawk Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07470853·Phase 1·Recruiting

Apply to this trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

for Bladder Cancer

12 locations incl. Duarte

Sponsor: EvolveImmune United, Inc

Sex: All·Age: 18+

Code: NCT07217171·Phase 1·Recruiting

Apply to this trial

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

for Lymphoma

14 locations incl. Aurora

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT07015242·Phase 2·Recruiting

Apply to this trial

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

for Locally Advanced Solid Tumor

20 locations incl. Orange

Sponsor: Nuvalent Inc.

Sex: All·Age: 12+

Code: NCT05118789·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of AVZO-021 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

11 locations incl. New Haven

Sponsor: Avenzo Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05867251·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

for Lymphoma

Drug: Glofitamab

17 locations incl. La Jolla

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06624085·Phase 1·Recruiting

Apply to this trial

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

for Advanced Solid Tumor

14 locations incl. Gilbert

Sponsor: Fate Therapeutics

Sex: All·Age: 18+

Code: NCT06241456·Phase 1·Recruiting

Apply to this trial

Study of Olutasidenib and Temozolomide in HGG

for High Grade Glioma

11 locations incl. Aurora

Sponsor: Rigel Pharmaceuticals

Sex: All·Age: 12 - 39

Code: NCT06161974·Phase 2·Recruiting

Apply to this trial

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

11 locations incl. Los Angeles

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06589596·Phase 1·Recruiting

Apply to this trial

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

for Platinum-resistant Ovarian Cancer

13 locations incl. Little Rock

Sponsor: Context Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06515613·Phase 1·Recruiting

Apply to this trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

for Hepatocellular Carcinoma

12 locations incl. Beverly Hills

Sponsor: Replimune, Inc.

Sex: All·Age: 18+

Code: NCT05733598·Phase 2·Recruiting

Apply to this trial

Conditions in Oncology (Philadelphia, PA)

Solid tumor· 61 Non-small cell lung cancer (NSCLC)· 42 Breast cancer· 41 Cancer (any)· 41 Colorectal cancer· 25 Acute myeloid leukemia (AML)· 25 Prostate cancer· 23 Ovarian cancer· 23 Pancreatic cancer· 19 Endometrial cancer· 18 Non-Hodgkin lymphoma· 18 Head and neck cancer· 17 Glioma· 14 Diffuse large B-cell lymphoma (DLBCL)· 14 Gastric cancer· 13 Bladder cancer· 13 Hematologic malignancy· 13 Multiple myeloma· 12 Melanoma· 11 Lung cancer· 10 Glioblastoma· 10 Leukemia (other)· 10 Myelodysplastic syndromes (MDS)· 10 Liver cancer· 9 Metastatic prostate cancer· 9 Kidney cancer· 9 Esophageal cancer· 8 Fallopian tube cancer· 8 Chronic lymphocytic leukemia (CLL)· 8 Neuroblastoma· 8 Pediatric cancer· 8 Neuroendocrine tumors· 8 Metastatic breast cancer· 7 Biliary tract cancer· 7 Cervical cancer· 7 Hodgkin lymphoma· 6 Triple-negative breast cancer· 5 Gastroesophageal junction cancer· 5 Small lymphocytic lymphoma· 5 Osteosarcoma· 5 Ewing sarcoma· 5 Acute lymphoblastic leukemia· 4 Myelofibrosis· 4 Follicular lymphoma· 4 HER2-positive breast cancer· 3 HER2-negative breast cancer· 3 Small cell lung cancer· 3 Metastatic colorectal cancer· 3 Myeloproliferative neoplasm· 3 Mantle cell lymphoma· 3 Burkitt lymphoma· 3 Thyroid cancer· 3 Gastrointestinal cancer· 2 Uterine cancer· 2 Brain cancer· 2 Chronic myelomonocytic leukemia· 2 Marginal zone lymphoma· 2 Soft tissue sarcoma· 2 Rhabdomyosarcoma· 2 Brain metastases· 1 Skin cancer· 1 Sarcoma· 1 Mesothelioma· 1